A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
An open-label multi-center phase II study to evaluate the efficacy and safety of anti-PD-1/CTLA-4 bispecific antibody AK104 alone or in combination with lenvatinib in patients with advanced hepatocellular carcinoma.
Hepatocellular Carcinoma
BIOLOGICAL: AK104 lenvatinib|BIOLOGICAL: AK104
Objective response rate (ORR), ORR is defined as the proportion of subjects with confirmed CR or PR, based on RECIST v1.1., Up to 2 years
Disease control rate (DCR), The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for â‰¥8 weeks) based on RECIST Version 1.1., Up to 2 years|Duration of response (DoR), Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first, Up to 2 years|Progression-free survival (PFS), Progression-free survival is defined as the time from the start of treatment with AK104 until the first documentation of disease progression or death due to any cause, whichever occurs first, Up to 2 years|Number of participants with adverse events (AEs), An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment, the time of informed consent signed through 90 days after the last dose of AK104 and Lenvatinib
This is a multi-center, multi-cohort, open-label phase 2 clinical study to evaluate the anti-tumor activity, safety, PK profile, immunogenicity and potential biomarkers of AK104 alone or in combination with for the treatment of advanced hepatocellular carcinoma